CME/CE Quiz

Supplements and Featured Publications, Managing the Expanded Use of Biologics Across Therapeutic Areas: An Example From B-Cell Targeted The, Volume 12, Issue 2 Suppl

Method of Participation:

Participants must:

  • Read the learning objectives and faculty disclosures.
  • Complete and submit the post-test with a pass rate of 70% or higher.
  • Complete and submit the attendance verification form.

A statement of credit will be issued only upon receipt of completed evaluation forms, a completed post-test with a score of 70% or higher, and a completed attendance verification form. Your statement of credit will be e-mailed to you 6 to 8 weeks after receipt.

Instructions

After reading "Managing the Expanded Use of Biologics Across Therapeutic Areas: An Example From B-Cell Targeted Therapies," please complete the program evaluation and circle the 1 best answer to each of the following questions.

1. Biopharmaceuticals are most commonly defined as:

  • Drugs that are produced through biological processes that structurally replace compounds within the body.
  • Drugs that are produced through artificial processes that assist in disease treatment.

2. Omalizumab is approved for which of the following indications?

  • Moderate-to-severe persistent allergic asthma and prevention of peanut-induced allergic reactions
  • Moderate-to-severe persistent allergic asthma and allergic rhinitis
  • Prevention of peanut-induced allergic reactions

3. Exenatide, an injectable incretin mimetic, was approved in 2005 for the adjunctive treatment of:

  • Type 1 diabetes.
  • Type 2 diabetes.

4. Which of the following drug categories slow or halt the progression of rheumatoid arthritis?

  • Glucocorticoids, DMARDs, analgesics, B-cell targeting
  • Analgesics, glucocorticoids, biologic response modifiers, IL-1 blockers

5. Which of the following agents are approved for patients with rheumatoid arthritis who have inadequate response to methotrexate?

  • Infliximab
  • Rituximab

6. B-cell blockers have the potential to be used as treatment in many different diseases.

  • False

7. Which of the following diseases is the top target of biopharmaceuticals in late-stage development?

  • Heart disease
  • Rheumatoid arthritis

8. Etanercept is approved for which of the following disease states?

  • Adult rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
  • Adult rheumatoid arthritis

9. Rosiglitazone is currently under investigation for which of the following?

  • Plaque psoriasis
  • Type 2 diabetes

10. Traditionally, infused drugs have been covered under which of the following benefit types?

  • Pharmacy

GOAL

To enhance understanding of the therapeutic targets common to many disease states that have led to expanded indications for many already approved drugs and the clinical and management challenges of using biologics with multiple indications.

TARGET AUDIENCE

Managed care pharmacy directors, medical directors, and other managed care executives responsible for overseeing the use of biologics and managing them on behalf of health plans.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

  • Recognize that common physiologic mechanisms, such as tumor necrosis factor-a, B-cells, and immunoglobulin E, are implicated in many disease states and are common targets for expanding indications for therapies approved by the US Food and Drug Administration (FDA).
  • Understand the benefits to managed care pharmacy associated with usage expansion, such as enhanced clinical outcomes, real-world knowledge of the drug, and potentially more competitive contracting arrangements.
  • Describe aspects of a management plan for dealing with implications of expanded indications for formulary decision makers.

Initial Live Release Date: October 6, 2005

Release Date: April 1, 2006

Expiration Date: March 31, 2007

If the participant has previously attended this program and requested or received credit, he/she may not request or receive credit for the home study version of the program.

FEES

There are no fees associated with this continuing education offering.

FUNDING

Genentech has provided the grant funds for this activity.

Credit Designation:

The University of Utah College of Pharmacy designates this continuing education activity for 1.5 credit hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Program Number: 068-999-05-049-H01.

The University of Utah College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The University of Utah School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Utah School of Medicine designates this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The University of Utah College of Pharmacy and the University of Utah School of Medicine do not recommend the use of any agent outside of the labeled indications.

MEDIA

Journal article learning activity.